Nordion Inc (NDN.TO)

BUY ON WEAKNESS
Feels it's in an interesting turnaround and they are starting to look at. Would consider at $17.50/18.
DON'T BUY
Has not been transparent to investors with respect to what's going on in its business and its accounting. A “Show Me” stock.
WAIT
Proteomics is executing their well in a difficult environment. The US lab business has not done well and expects they will sell it. Still frustrated that there are no concrete numbers that he can't hold them accountable to. Have to see more visibility
TOP PICK
A bit of a laggard. Long-term chart indicates that it did not take out its low this year and starting to break out over its trend line. Volume is starting to come in.
BUY
Has been languishing. Now is quite a good entry point. Relatively safe.
HOLD
A very good company. Expect they will go through some restructuring. Need to see some form of catalyst to improve the earnings growth outlook and to exit some of their businesses that are not profitable.
BUY
Not sure why they are lagging.
DON'T BUY
Seems to be highly regulated by provincial ministries of health.Afraid that this could cut into profits.
BUY ON WEAKNESS
A one-year target of $22/23.Would buy around the $16/17 mark.
HOLD
Can't seem to get all the engines firing at the same time. Sell on any rally.
DON'T BUY
Has been a pretty weak performer in a strong sector.
DON'T BUY
Have a model price of $21. Fully valued.
WAIT
If it breaks through the 2 lows of around $18, it will really drop.
DON'T BUY
Has an interesting basket of venture capital businesses which have created some problems. Will take a while for the stock to settle down. Be patient.
DON'T BUY
Performance has been poor. Starting to look at this stock now. Still somewhat pricey.
Showing 46 to 60 of 229 entries